AveXis, Inc. (AVXS) Analysts See $-1.51 EPS

February 18, 2018 - By Migdalia James

 AveXis, Inc. (AVXS) Analysts See $ 1.51 EPS

Analysts expect AveXis, Inc. (NASDAQ:AVXS) to report $-1.51 EPS on March, 15.They anticipate $0.59 EPS change or 64.13 % from last quarter’s $-0.92 EPS. After having $-1.52 EPS previously, AveXis, Inc.’s analysts see -0.66 % EPS growth. The stock increased 0.38% or $0.44 during the last trading session, reaching $116.55. About 338,308 shares traded. AveXis, Inc. (NASDAQ:AVXS) has risen 95.85% since February 18, 2017 and is uptrending. It has outperformed by 79.15% the S&P500.

AveXis, Inc. (NASDAQ:AVXS) Ratings Coverage

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. Goldman Sachs maintained AveXis, Inc. (NASDAQ:AVXS) rating on Friday, May 13. Goldman Sachs has “Buy” rating and $47 target. Bank of America initiated the stock with “Buy” rating in Friday, October 21 report. The firm has “Buy” rating given on Monday, September 19 by Jefferies. The firm has “Market Perform” rating given on Friday, July 15 by Wells Fargo. The firm earned “Buy” rating on Friday, August 12 by Jefferies.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $4.25 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

More recent AveXis, Inc. (NASDAQ:AVXS) news were published by: Globenewswire.com which released: “AveXis Announces Closing of Public Offering of Common Stock and Full Exercise …” on January 22, 2018. Also Marketwatch.com published the news titled: “Gene therapy stocks slammed after scientist reveals safety concerns” on January 30, 2018. Globenewswire.com‘s news article titled: “AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS …” with publication date: January 30, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.